Tacrolimus: A Review of its Pharmacology, and Therapeutic Potential in Hepatic and Renal Transplantation

Drugs

Volumn 46, Issue 4, 1993, Pages 746-794

  Peters, David H ^a   Fitton, Andrew ^a   Plosker, Greg L ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BROMOCRIPTINE; CLOTRIMAZOLE; CORTICOSTEROID; CORTICOSTERONE; CYCLOSPORIN; CYTOCHROME P450; DILTIAZEM; ERGOTAMINE; ERYTHROMYCIN; ETHINYLESTRADIOL; FLUCONAZOLE; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; JOSAMYCIN; KETOCONAZOLE; METHYLPREDNISOLONE; MICONAZOLE; MIDAZOLAM; NIFEDIPINE; OKT 3; OMEPRAZOLE; PREDNISOLONE; STEROID; TACROLIMUS; TROLEANDOMYCIN; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; B LYMPHOCYTE ACTIVATION; DIABETOGENESIS; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; FATIGUE; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; GRAFT SURVIVAL; HEADACHE; HUMAN; HUMAN CELL; HYPERKALEMIA; IMMUNOMODULATION; INFECTION; INSOMNIA; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER FUNCTION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RAT; REVIEW; T LYMPHOCYTE ACTIVATION; TREMOR;

ADULT; CHILD, PRESCHOOL; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; TACROLIMUS; TREATMENT OUTCOME;

ANIMALIA;

EID: 0027485716     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199346040-00009     Document Type: Article

References (330)

1. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver
2. Acute hemolytic anaemia in liver and bone marrow transplant patients under FK 506 therapy
3. Infections with FK 506 immunosuppression: preliminary results with primary therapy
4. Infections in adult liver transplant patients under FK 506 immunosuppression
5. Effects of FK 506 on human hepatic microsomal cytochrome P450-dependent drug metabolism in vitro
6. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level
7. Limb allografts in rats immunosuppressed with FK506
8. Reduction of leucocyte adherence and emigration by cyclosporine and L683,590 (FK506) in postcapillary venules
9. The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1
10. Cyclosporin A and FK-506 both affect DNA binding of regulatory nuclear proteins to the human interleukin-2 promoter
11. Effect of FK-506 and cyclosporine on human lymphocyte responses in vitro
12. The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance
13. 2 in cyclosporine A nephrotoxicity
14. FK 506: monitoring in plasma or in whole blood
15. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin
16. The effect of the immunosuppressant FK-506 on alternate pathways of T-cell activation
17. Mechanisms of immuno-suppression by FK506
18. Probing immunosuppressant action with a nonnatural immunophilin ligand
19. Acute effects of FK506 and cyclosporine A on cultured human proximal tubular cells
20. Anti-proliferative effect of FK 506 and cyclosporine on adult human hepatocytes in culture
21. FK 506 has no short-term effects on endogenous or exogenous myeloid reconstitution in irradiated mice
22. FK 506 and xenogeneic human anti-porcine cellular reactivity
23. The immunosuppressives FK-506 and cyclosporin-A inhibit the generation of protein factors binding to the 2 purine boxes of the interleukin-2 enhancer
24. Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506
25. Assay of FK 506 in plasma
26. Observations about FK-506 in primates
27. FK-506-associated diabetes mellitus in the pediatric transplant population is a rare complication
28. FK506 and rapamycin: novel pharmacological probes of the immune response
29. In vitro metabolism of FK506, cytochrome P450 and drug interactions
30. High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile and urine of liver grafted patients
31. Interactions of FK 506 and cyclosporine metabolism
32. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites
33. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation
34. FK-506 in experimental renal allografts
35. Update on liver transplantation
36. Contingent genetic regulatory events in T lymphocyte activation
37. Transplantation of pediatric en bloc kidneys under FK 506 immunosuppression
38. Immunosuppressants at work
39. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy — a clinicopathologic study in 96 patients
40. Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine
41. Characterization of the anti-inflammatory effect of FK-506 on human mast cells
42. cεRI+ cells
43. Anti-inflammatory effect of FK-506 on human skin mast cells
44. FK 506 fails to reverse moderate cardiac allograft rejection in a canine heterotopic model
45. The salutary effect of FK506 in ischemia-reperfusion injury of the canine liver
46. A critical appraisal of renal transplantation
47. Psychiatric morbidity in liver transplant patients
48. Differential modulation of IL-1-induced IFN-γ production by the immunosuppressive macrolides rapamycin (RAP) and FK-506
49. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells
50. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin
51. The immunosuppressive and toxic actions of FK-506 are mechanistically related
52. Neurologic complications of FK 506
53. Effects of FK 506 and cyclosporine on T-cell activation: integrin-mediated adhesion of T cells, proliferation, and maturation of cytotoxic T cells
54. The effect of FK506 treatment on pancreaticoduodenal allotransplantation in the primate
55. FK 506 enhances the beneficial effects of donor-specific blood transfusion on allograft survival in rats
56. Does FK 506 pretreatment promote healing following acute chemical injury in the rat? Abstract
57. FK 506: a new immunosuppressive agent for organ transplantation. Pharmacology, mechanism of action and clinical applications
58. Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats
59. FK 506 modulates D-galactosamine-induced hepatitis in rats
60. Cyclosporin: A review of its phrmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders
61. Protein kinase activation and the immunosuppressant cyclosporine
62. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A
63. Initial experience with FK 506 as an immunosuppressant for non-human primate recipients of cardiac allografts
64. FK-506 and cyclosporin: selective inhibition of calcium ionophore induced polymorphonuclear leukocyte degranulation
65. Augmentation of rat liver regeneration by FK 506 compared with cyclosporine
66. Studies on mechanisms of augmentation of liver regeneration by cyclosporine and FK 506
67. FK 506 as a growth control factor
68. Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient
69. Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation
70. A combined HPLC-ELISA evaluation of FK-506 in transplant patients
71. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A
72. Effect of a novel immunosuppressive agent, FK506, on mitogen-induced inositol phospholipid degradation in rat thymocytes
73. Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment
74. Effect of donor-specific transfusion and FK 506 on small intestine allotransplantation
75. A randomised trial of primary liver transplantation under immunosuppression with FK506 vs cyclosporine
76. Adverse effects associated with the use of FK 506
77. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls
78. Transcription of the tumor necrosis factor α gene is rapidly induced by anti-immunoglobulin and blocked by cyclosporin A and FK506 in human B cells
79. The antibody crossmatch in liver transplantation
80. Liver transplantation under cyclosporins: a decade of experience
81. FK-506 and islet transplantation: a potential protocol for inducing tolerance
82. Tolerance induction by liver grafting and FK 506 treatment in nonhuman primates
83. Cytoim-munologic monitoring of small bowel allograft recipients
84. The effect of immunosuppressive agents on the induction of nuclear factors that bind to sites on the interleukin 2 promoter
85. Infectious complications of pediatric liver transplantation under FK 506
86. A whole blood FK 506 assay for the IMx® analyzer
87. FK 506 in canine renal transplantation
88. Blood protein binding (BPB) of FK-506 (F) in various species. Abstract
89. FK506 and rapamycin selectively enhance degradation of IL-2 and GM-CSF mRNA
90. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase
91. Substrate specificities of the peptidyl pro-lyl cis-trans isomerase activities of cyclophilin and FK-506 binding protein: evidence for the existence of a family of distinct enzymes
92. Combination use of suboptimal dose of FK 506 and cyclosporine in canine lung transplantation
93. Effect of FK 506 on bowel transplantation in rats
94. Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production
95. FK 506: short- and long-term treatment after cardiac transplantation in nonhuman primates
96. Mutagenicity test of tacrolimus (FK506)
97. Prolonged lung allograft survival with a short course of FK 506
98. Effects of immunosuppressants, FK506, deoxyspergualin, and cyclosporine A on immature human hematopoiesis
99. The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease
100. Immuno-philin ligands demonstrate common features of signal trans-duction leading to exocytosis or transcription
101. Prolonged survival of small intestinal allograft in the rat with cyclosporine A, FK 506, and 15-deoxyspergualin
102. Stimulation of liver regeneration by pretreatment with azathioprine as well as cyclosporine and FK506
103. Histopathological study of canine pancreaticoduodenal allo-transpantation with FK506, cyclosporine, and triple regimen immunosuppression
104. Effects of FK506 and 15-deoxyspergualin in rat orthotopic liver transplantation
105. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK-506
106. FK 506 and orthotopic liver transplantation in the rat
107. Pharmacokinetics of FK 506 in liver transplant recipients after continuous intravenous infusion
108. Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplantation
109. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations
110. Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506
111. Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration
112. Japanese study of FK 506 on kidney transplantation: results of an late phase II study
113. Morphological characteristics of renal allografts showing renal dysfunction under FK 506 therapy: is graft biopsy available to reveal the morphological findings corresponding with FK 506 nephropathy
114. Antigen-induced apoptosis in developing T cells: a mechanism for negative selection of the T cell receptor repertoire
115. Pediatric renal transplantation under FK 506 immunosuppression
116. Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro
117. Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical
118. Cyclosporin A and FK-506: effects on platelet function
119. Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium
120. FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression
121. Monitoring FK 506 concentrations in plasma and whole blood
122. Immunosuppressive effects of FK 506 and 15-deoxyspergualin in rat lung transplantation
123. A protective effect of FK506 in ischaemically injured rat livers
124. T lymphocyte activation through the CD28 pathway is insensitive to inhibition by the immunosuppressive drug FK-506
125. Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506
126. The mechanism of action of the immunosuppressive drug FK-506
127. The mechanism of action of FK 506
128. Effects of an immunosuppressant, FK506, on interleukin la production by human macrophages and a macrophage-like cell line, U937
129. The effect of FK506 on segmental pancreas allografts in mongrel dogs
130. Sensitivity of intracellular signals responsible for cell cycle progression to cyclosporine
131. FK-506, a novel immunosuppressant isolated from a Streptomyces
132. FK-506, a novel immunosuppressant isolated from a Streptomyces
133. Effect of FK-506 on human mixed lymphocyte reaction in vitro
134. Suppression of corneal graft rejection in rabbits by a new immunosuppressive agent, FK-506
135. FK 506 assay past and present- characteristics of FK 506 ELISA
136. Role of endothelin in cyclosporine-induced glomerular dysfunction
137. Lymphocyte-T antigen interaction in transplant rejection
138. Effects of cyclosporin A and FK506 on ischemia/reperfusion-induced neutrophil infiltration in the cat
139. FK506 induced nephrotoxicity in rats
140. Experimental studies of vascularized allogeneic limb transplantation in the rat using a new immunosuppressive agent, FK-506: morphological and immunological analysis
141. Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation
142. Early infections in kidney transplant recipients under FK 506
143. Effect of FK 506 on B-cell responses
144. Evaluation of calcineurin’s role in the immunosuppressant activity of FK 506, related macrolactams, and cyclosporine
145. Indefinite small bowel allograft survival after limited immunosuppressive therapy is not due to specific hyporesponsiveness
146. Pharmacokinetics of tacrolimus (FK506) in liver transplant patients
147. Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy
148. The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506
149. FK 506 is a direct glomeruloconstrictor, as determined by electrical resistance pulse sizing (ERPS)
150. FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes
151. FK 506 and cyclosporin, molecular probes for studying intracellular signal transduction
152. Inhibition of T cell signalling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity
153. Calcineurin is a common target of cyclophilin-cyclosporin and FKBP-FK506 complexes
154. Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506
155. Effect of temperature and hematocrit on plasma concentration of FK 506
156. Effects of in vivo treatment with FK506 on natural killer cells in rats
157. The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes
158. NF-ATp, a lymphocyte-T DNA-binding protein that is a target for calcineurin and immunosuppressive drugs
159. The nephrotoxicity of FK506 as compared with cyclosporine
160. Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation
161. Renal function after conversion from cyclosporine to FK 506 in liver transplant patients
162. The effects of FK506 on renal function after liver transplantation
163. Changes in renal function after liver transplantation under FK 506
164. The question of FK 506 nephrotoxicity after liver transplantation
165. Differences in oral FK506 dosae requirements between adult and pediatric liver transplant patients
166. Evaluation of a novel, intelligent, dosing system for optimizing FK 506 therapy
167. The effect of food on oral bioavailability of tacrolimus (FK506) in liver transplant patients
168. Cyclosporine, FK506, and rapamycin
169. Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients
170. Interaction between FK506 and clotrimazole in a liver transplant recipient
171. A potent immunosuppressive effect of FK 506 in orthotopic liver transplantation in primates
172. Liver retransplantation in adults: overall results and determinant factors affecting the outcome
173. The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes
174. Pancreaticoduodenal allotransplantation with FK 506 in the dog
175. Protective effects of cyclophosphamide, cyclosporin A and FK506 against antigen-induced lung eosinophilia in guinea-pigs
176. Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation
177. Disruption of renal function and gene expression by FK 506 and cyclosporine
178. FK506-induced kidney tubular cell injury
179. Suppression of allograft rejection with FK506
180. FK506 suppression of heart and liver allograft rejection
181. Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine
182. Radioreceptor assay for quantifying FK-506 immunosuppressant in whole blood
183. The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis
184. Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population
185. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression
186. Experience with posttransplant lymphoproliferative disorders in solid organ transplant recipients
187. Antigen-dependent increase in cytosolic free calcium in specific human T-lymphocyte clones
188. Summary of the first international FK 506 congress: perspectives and prospects
189. Optimal serum trough levels of FK506 in renal allotransplantation of the beagle dog
190. Prolongation of canine renal allograft survival by treatment with FK-506
191. Studies on the effects of FK-506 on renal allografting in the beagle dog
192. Studies on the induction and maintenance of long-term graft acceptance by treatment with FK-506 in heterotropic cardiac allotransplantation in rats
193. Effects of combination treatment with FK 506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs
194. Studies on FK506 in experimental organ transplantation
195. The effect of short-term FK 506 therapy on pancreas transplantation in rats
196. Enhanced liver regeneration by FK 506 can be blocked by interleukin-1α and interleukin-2
197. FK506-and CSA- sensitive activation of the interleukin-2 promoter by calcineurin
198. FK 506 inhibition of cyclosporine metabolism by human liver microsomes
199. Long-term impact of HLA matching on kidney graft survival in cyclosporine-treated recipients
200. CMV retinitis and the use of FK 506
201. FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function
202. FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat
203. Effect of FK 506 on human hepatic cytochromes P-450: interaction with CyA
204. Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients
205. Influence of FK 506 on the thymus
206. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506
207. Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression
208. Expressive dysphasia possibly related to FK506 in two liver transplant recipients
209. Post-transplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression
210. Polypeptide chain binding proteins: catalysts of protein folding and related processes in cells
211. Drug interactions with FK 506. Abstract
212. Analysis of long-term acceptance of xenografts in rats induced by short-term administration of FK506
213. Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation — incidence, location, and severity in cyclosporin- and FK506-treated patients
214. FK-506 pretreatment is associated with reduced levels of tumor necrosis factor and interleukin 6 following hepatic ischemia/reperfusion
215. FK 506 ameliorates the hepatic injury associated with ischemia and reperfusion in rats
216. The protective effect of FK506 pretreatment against renal ischemia/reperfusion injury in rats
217. Mechanism of the inhibition of T cell activation by immunosuppressant FK506. Abstract
218. Pancreaticoduodenal allotransplantation with cyclosporine and FK506
219. Comparative study of FK506, cyclosporine, and triple regimen immunosuppression with FK 506, cyclosporine and mizoribine
220. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat
221. Novel immunosup-pressive agent, FK 506
222. New onset diabetes in FK-506 vs cyclosporine-treated kidney transplant recipients
223. Chemistry and biology of the immunophilins and their immunosuppressive ligands
224. The mechanism of action of cyclosporin A and FK506
225. Effects of FK 506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro
226. Kidney transplantation under FK 506 immunosuppression
227. FK 506 in kidney transplantation
228. Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: a preliminary report
229. Effect of FK 506 on experimental liver carcinogenesis
230. A cytosolic binding protein for the immunosuppressant FK-506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin
231. FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin
232. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction
233. Observations on the mechanism of action of FK 506
234. New horizons in immunosuppression
235. FK 506 and rapamycin inhibit murine T cell activation through different mechanisms
236. Differential effects of the immunosuppressive macrolides FK-506 and rapamycin on activation-induced T cell apoptosis
237. Transplantation
238. Hepatotrophic effects of FK 506 in dogs
239. FK 506 for liver, kidney, and pancreas transplantation
240. Liver transplantation: An unfinished product
241. A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent
242. Immunosuppressive activity, lymphocyte subset analysis and acute toxicity of FK 506 in the rat: a comparative and combination study with cyclosporine
243. The effects of immunosuppressive agents on in vitro production of human immuno-globulins
244. 2+- and calmodulin-dependent protein phosphatase
245. Metabolism of FK 506 in differentially induced rat liver microsomes
246. Standard sequential immunosuppression with Minnesota antilymphoblast globulin and cyclosporine vs FK 506: a comparison of early nephrotoxicity
247. Activation of transcription factor NFκB in Jurkat cells is inhibited selectively by FK506 in a signal-dependent manner
248. Cyclosporine toxicity in the isolated perfused rat kidney
249. Nephrotoxic potential of FK 506
250. Effects of a novel immunosuppressive agent, FK506, on human B-cell activation
251. Long-term insulin requirement after liver transplantation with FK 506 in american veterans
252. Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection
253. Effects of FK506 on rat thymus: time-course analysis by immunoperoxidase technique and flow cytofluorometry
254. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors
255. Retransplantation of liver: a comparison of FK 506 and cyclosprine-treated patients
256. Effect of FK 506 on survival of rat small bowel allografts
257. A highly sensitive method to assay FK-506 levels in plasma
258. Physicochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis
259. The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors
260. The immunosuppressant FK 506 selectively inhibits expression of early T cell activation genes
261. Renal transplantation in baboons under FK-506
262. Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids
263. One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults
264. Orthotopic liver transplantation in dogs receiving FK-506
265. Immunosuppression of canine, monkey and baboon allografts by FK506: with special reference to synergism with other drugs and to tolerance induction
266. The spectrum of aspergillosis in liver transplant patients: comparison of FK 506 and cyclosporine immunosuppression
267. Isolation and sequence of an FK 506-binding protein from N. crassa which catalyses protein folding
268. Selective immunosuppression of prodigiosin 25-C and FK506 in the murine immune system
269. Use of FK 506 in pediatric patients
270. FK 506 versus cyclosporine in pediatric liver transplantation
271. Two-year experience with FK 506 in pediatric patients
272. FK 506-an effective immunosuppressant for achieving long-term functional islet allograft survival in diabetic rats
273. Influence of FK 506 on renal blood flow
274. Induction of graft acceptance after dog kidney or liver transplantation
275. Experience with FK506 in living-related liver transplantation
276. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation
277. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection
278. Use of prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation
279. Effect of FK 506 on orthotopic small bowel transplantation in rats
280. Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression
281. FK 506 reduces the injury experienced following renal ischemia and repefusion
282. Pharmacokinetics of FK 506: preclinical and clinical studies
283. Pharmacokinetics of FK 506 in transplant patients
284. Biopharmaceutical aspects of FK-506
285. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism
286. An attempt to induce tolerance to skin grafts in congenic mice with FK 506
287. 31P nuclear magnetic resonance spectroscopy in vivo
288. Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506
289. FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line
290. Distribution of FK 506 in plasma lipoproteins in transplant patients
291. Practical aspects of FK 506 analysis (Pittsburgh experience)
292. FK 506 measurement: comparison of different analytical methods
293. Effect of FK-506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro
294. Effects of FK-506 and cyclosporine on human T and B lymphoproliferative responses
295. Transplantation of paediatric donor kidneys to adult patients
296. Suppression of B-cell activation by cyclosporin-A, FK506 and rapamycin
297. Hyperuricemic acute renal failure associated with FK506 nephrotoxicity
298. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients
299. Plasma level-guided low-dose FK506 therapy in patients with early liver dysfunction after liver transplantation
300. Antigen presentation and HLA-DR expression by FK-506-treated human monocytes
301. Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats
302. The influence of FK-506 and low-concentration cyclosporin on human lymphocyte activation, antigen expression and blastogenesis: a flow cytometric analysis
303. Spleen lymphocyte populations and expression of activation markers in rats treated with the potent new immunosuppressive agent FK-506
304. FK 506 inhibits the development of transplant arteriosclerosis
305. Interaction between FK 506 and cyclosporine in dogs
306. Prominent prolongation of islet xenograft survival in combination therapy with FK 506 and 15-deoxyspergualin
307. HLA matching in liver transplantation
308. Short-term FK 506-induced morphological changes in rat kidneys
309. FK 506-induced juxtaglomerular apparatus hyperplasia and tubular damage in rat kidney- morphologic and biologic analysis
310. 2 in the kidney
311. Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506
312. FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat
313. Effects of a novel immunosuppressive agent, FK-506, on islet allograft survival in the rat
314. Comparative studies of FK506 and cyclosporine in canine orthotopic hepatic allograft survival
315. Canine total orthotopic small bowel transplantation under FK 506
316. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro
317. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro
318. Mutagenicity of the new immunosuppressive drugs, FK 506, and spergualin
319. Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A
320. Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA
321. Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression
322. Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection